Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and Permeation Enhancement.
| Journal | AAPS PharmSciTech |
| Study Type | Clinical Study |
| Population | Human participants |
Oral cannabinoid bioavailability remains a significant clinical challenge, with first-pass metabolism reducing CBD bioavailability to as low as 6%. This comprehensive review of oral mucosal delivery systems addresses a critical gap in optimizing cannabinoid therapeutics for patients who need consistent, predictable dosing.
This pharmaceutical review examines oral mucosal delivery technologies for cannabinoids, including fast-dissolving films, mucoadhesive matrices, and in situ gels that bypass hepatic first-pass metabolism. The authors evaluate fabrication methods like solvent casting, hot melt extrusion, and 3D printing for creating dosage forms that enhance cannabinoid bioavailability through transmucosal absorption. Key advantages include rapid onset, sustained release profiles, and improved systemic exposure compared to traditional oral administration. The review highlights formulation strategies to overcome cannabinoids’ poor water solubility and pharmacokinetic limitations.
“While these delivery technologies show promise in laboratory settings, we still lack robust clinical data comparing bioavailability and patient outcomes with these novel formulations versus existing products. Until we have head-to-head pharmacokinetic studies in patients, I remain cautiously optimistic about their clinical impact.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Why do traditional oral cannabinoid formulations have poor clinical outcomes?
Cannabinoids like CBD and THC suffer from poor aqueous solubility and extensive first-pass hepatic metabolism when taken orally, leading to low and inconsistent bioavailability. This results in unpredictable therapeutic effects and necessitates higher doses to achieve clinical benefit.
How do oral mucosal delivery systems improve cannabinoid therapy?
Oral mucosal delivery systems enable transmucosal absorption directly into systemic circulation, bypassing first-pass metabolism in the liver. This approach provides more predictable pharmacokinetics, faster onset of action, and improved bioavailability compared to traditional oral administration.
What types of oral mucosal cannabinoid formulations are being developed?
Current formulations include fast-dissolving films, mucoadhesive matrices, in situ gels, and particulate systems. These dosage forms are designed to optimize cannabinoid residence time in the oral cavity and enhance permeation through mucosal tissues.
Which fabrication techniques show the most promise for cannabinoid oral films?
Solvent casting, hot melt extrusion, and emerging 3D printing methods are the primary fabrication techniques being explored. Each method offers distinct advantages for controlling drug release profiles and incorporating permeation enhancers to improve cannabinoid absorption.
What clinical conditions could benefit most from improved cannabinoid oral mucosal delivery?
Chronic pain, neurological disorders, and cancer-associated symptoms represent the primary therapeutic targets due to cannabinoids’ broad-spectrum pharmacological activity. Enhanced bioavailability through mucosal delivery could provide more consistent symptom control for these challenging conditions.
